Cidara Therapeutics Announces Promotion of Nicole Davarpanah to Chief Medical Officer and Corrina Pavetto to SVP, Clinical Development

Core Insights - Cidara Therapeutics has announced the promotion of Nicole Davarpanah to Chief Medical Officer and Corrina Pavetto to Senior Vice President of Clinical Development, effective May 1, 2025, during a critical phase of their influenza antiviral candidate CD388's development [1][2] Company Developments - The promotions are significant as Cidara advances its influenza antiviral candidate CD388 through the Phase 2b NAVIGATE trial and prepares for Phase 3 [2] - Dr. Davarpanah has over a decade of clinical development experience, previously holding leadership roles at Genentech/Roche, where she was responsible for early-stage molecules' advancement through clinical development and FDA approval [2][3] - Ms. Pavetto brings over 25 years of experience in clinical research and regulatory affairs, with a focus on infectious diseases, and has previously supported influenza antiviral and vaccine development at BARDA [4] Product Pipeline - Cidara's lead drug-Fc conjugate candidate, CD388, is designed for universal prevention of seasonal and pandemic influenza with a single dose by inhibiting viral proliferation [5] - CD388 received Fast Track Designation from the FDA in June 2023, and the company completed enrollment of its 5,000 patient Phase 2b NAVIGATE trial in December 2024 [5]